- Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
More ▼
Key statistics
On Thursday, Halozyme Therapeutics Inc (HALO:NSQ) closed at 43.92, -4.85% below its 52-week high of 46.16, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 45.44 |
---|---|
High | 45.56 |
Low | 43.75 |
Bid | 43.00 |
Offer | 46.69 |
Previous close | 43.92 |
Average volume | 1.00m |
---|---|
Shares outstanding | 127.27m |
Free float | 125.86m |
P/E (TTM) | 18.17 |
Market cap | 5.59bn USD |
EPS (TTM) | 2.42 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼